Endocyte Inc. Aktie
Deine Einschätzung
Was spricht für und gegen Endocyte Inc. in den nächsten Jahren?
Pro
?
M************
?
W******* i* V********
?
A****************
Kontra
?
L*********** I********** f** d** n******* J****
?
M****
?
U****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Endocyte Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Endocyte Inc. | - | - | - | - | - | - | - |
Ardelyx Inc. | 0,44 % | -8,48 % | 12,59 % | 75,43 % | 24,74 % | 28,75 % | - |
Evolus Inc | - | -4,13 % | 4,50 % | 26,09 % | 28,18 % | 57,82 % | - |
Salarius Pharmaceuticals Inc. | -2,36 % | 2,48 % | -4,17 % | -62,02 % | -25,41 % | -98,32 % | -99,99 % |
Kommentare
Endocyte is working on developing therapy to combat tumors
The company is also focused on developing promising companion agents for identifying patients most likely to benefit from its targeted therapy.
Endocyte is preparing to enter its adaptor-controlled CAR-T program in clinic in Q4 2018.
Lutetium-PSMA-617 is a promising radioligand therapy targeting advanced prostate cancer.